Understand the source comparison
SLU-PP-332 Dosage Exercise Mimetic 2026: Comparison
SLU-PP-332 ERRα/γ agonist activating PGC-1α transcription 10–50mg daily Mitochondrial biogenesis, fatty acid oxidation 18–22 hours Most research-validated exercise mimetic in 2026. Produces skeletal muscle adaptations comparable to endurance training without l
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SLU-PP-332
- ERRα/γ agonist activating PGC-1α transcription
- 10–50mg daily
- Mitochondrial biogenesis, fatty acid oxidation
- 18–22 hours
- Most research-validated exercise mimetic in 2026. Produces skeletal muscle adaptations comparable to endurance training without locomotor activity
- AICAR
- Direct AMPK activator
- 150–500mg daily
- Glucose uptake, glycogen depletion
- 6–8 hours
- Effective for acute metabolic shifts but lacks the transcriptional depth of receptor-mediated pathways. Used primarily for short-term insulin sensitivity research
- GW501516
- PPARδ agonist
- 10–20mg daily
- Fatty acid metabolism, endurance capacity
- 16–24 hours
- Potent for oxidative capacity but withdrawn from human trials in 2007 due to carcinogenic findings in rodent models. Relegated to in vitro research only
- Metformin
- AMPK activation via mitochondrial complex I inhibition
- 500–2000mg daily
- Hepatic glucose output reduction
- 4–6 hours
- Clinically approved but primarily glucose-regulating. Mitochondrial effects are secondary and less pronounced than SLU-PP-332's targeted transcriptional activation
- SLU-PP-332 occupies a unique position: it's the only compound in active Phase II trials (as of early 2026) that replicates the full transcriptional signature of chronic exercise without triggering the inflammatory or oxidative stress responses that accompany actual physical exertion.